- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Berlex to sell prefilled Magnevist syringes
Montville, NJ-based Berlex Laboratories has received Food and Drug Administration approval to market its Magnevist MRI contrast agent in prefilled syringes. The contrast company expects to begin shipments of the syringes in the first quarter of 1999.
Montville, NJ-based Berlex Laboratories has received Food and Drug Administration approval to market its Magnevist MRI contrast agent in prefilled syringes. The contrast company expects to begin shipments of the syringes in the first quarter of 1999. Prefilled syringes will come in 10-mL, 15-mL, and 20-mL sizes. Berlex believes that prefilled syringes will save time and reduce the potential for contamination and needle stick incidents that might occur when Magnevist syringes are filled manually.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
